Literature DB >> 17237659

Foundations of opioid risk management.

Nathaniel P Katz1, Edgar H Adams, James C Benneyan, Howard G Birnbaum, Simon H Budman, Ronald W Buzzeo, Daniel B Carr, Theodore J Cicero, Douglas Gourlay, James A Inciardi, David E Joranson, James Kesslick, Stephen D Lande.   

Abstract

Increased abuse and diversion of prescription opioids has been a consequence of the increased availability of opioids to address the widespread problem of undertreated pain. Opioid risk management refers to the effort to minimize harms associated with opioid therapy while maintaining appropriate access to therapy. Management of these linked public health issues requires a coordinated and balanced effort among a disparate group of stakeholders at the federal, state, industry, practitioner, and patient levels. This paper reviews the principles of opioid risk management by examining the epidemiology of prescription opioid abuse in the United States; identifying key stakeholders involved in opioid risk management and their responsibilities for managing or monitoring opioid abuse and diversion; and summarizing the mechanisms currently used to monitor and address prescription opioid abuse. Limitations of current approaches, and emerging directions in opioid risk management, are also presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237659     DOI: 10.1097/01.ajp.0000210953.86255.8f

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  33 in total

Review 1.  Nonmedical use of prescription opioids: motive and ubiquity issues.

Authors:  James P Zacny; Stephanie A Lichtor
Journal:  J Pain       Date:  2008-03-14       Impact factor: 5.820

Review 2.  Issues in long-term opioid therapy: unmet needs, risks, and solutions.

Authors:  Steven D Passik
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 3.  Abuse-deterrent opioid formulations: are they a pipe dream?

Authors:  Nathaniel Katz
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 4.  A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.

Authors:  Charles E Argoff; Daniel I Silvershein
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

5.  Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Joseph Stauffer; Beatrice Setnik; Marta Sokolowska; Myroslava Romach; Franklin Johnson; Edward Sellers
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  Opioid formulations with sequestered naltrexone: a perspective review.

Authors:  Robert Taylor; Robert B Raffa; Joseph V Pergolizzi
Journal:  Ther Adv Drug Saf       Date:  2014-06

7.  Cancer Pain Management and Bone Metastases: An Update for the Clinician.

Authors:  Guido Schneider; Raymond Voltz; Jan Gaertner
Journal:  Breast Care (Basel)       Date:  2012-04-27       Impact factor: 2.860

Review 8.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

9.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

10.  Can abuse deterrent formulations make a difference? Expectation and speculation.

Authors:  Simon H Budman; Jill M Grimes Serrano; Stephen F Butler
Journal:  Harm Reduct J       Date:  2009-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.